Prøve GULL - Gratis
Biopharma Chromatography: Segregating Opportunities of all Sizes
Bio Spectrum
|March 2025
Chromatography systems are essential in a variety of fields, including the biological sciences. Biopharma accounts for almost 30 per cent of this market, making it a key sector for chromatography systems. The main forces behind India's dominant market position would be the enabling government policies and the growing number of foreign research and industrial contracts. Beginning in 2028, India will create a demand for more than 1000 biopharma chromatography systems yearly.
-

Chromatography systems play a critical role across different industries, in processes like drug development, nutritional analysis, toxin detection, pollutant analysis, among others. This being one of the most preferred methods for the separation and purification of compounds across the aforementioned industries, its market share is worth $10+ billion as of 2025. Approximately 30 per cent of this market is driven by biopharma, making it a cornerstone industry for chromatography systems.
Biopharma Chromatography Market
Ever since the outbreak of COVID-19, the world has been on its toes regarding healthcare operations. Governments and the public have become more alert towards healthcare facilities and 2020 can be seen as a landmark year that reshaped several trends within the healthcare sector, including chromatography.
To tackle COVID-19 at its peak, the year 2020 saw the highest increase (>10 per cent higher compared to 2019) in global healthcare spending and the Biopharma sector saw its highest ever ~130 per cent increase in funding from $58 billion in 2019 to ~$134 billion in 2020. For chromatography systems specifically, the pandemic led to an increased usage of single-use systems (SUS) to avoid crosscontamination and to support the then-necessary rapid vaccine production. As a result, the acceptance of SUSs in different clinical and commercial production processes has increased from an average of ~50 per cent in 2019, to ~70 per cent in 2024.
Denne historien er fra March 2025-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Listen
Translate
Change font size